---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-011613"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:26:59.972908+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Femasys completes first in-office commercial FemaSeed infertility procedure

## Summary
- First commercial procedure using FDA-cleared FemaSeed intratubal insemination performed in Saginaw, Michigan.
- CEO cites FemaSeed as cost-effective, safer alternative to IVF amid Alabama Supreme Court frozen embryo ruling.
- Top-line pivotal data from FemaSeed study expected to be announced in Q1 2024.
- Procedure conducted by Dr. Andrew Wagner of Women's OB-GYN PC.

## SEC filing metadata
- accession: 0001140361-24-011613
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036124011613/0001140361-24-011613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036124011613/ef20023361_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-011613
- JSON: https://secwatch.observer/filing/0001140361-24-011613.json
- Plain text: https://secwatch.observer/filing/0001140361-24-011613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.